GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors

Yang, Yuqiong; Lu, Shuyang; Zeng, Wenqin; Xie, Shaolei; Xiao, Sheng-Jun

doi:10.1016/j.anndiagpath.2016.09.011

Cited by 26 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For mammaglobin, some cases showed weak staining in the non-signet-ring components while the signet-ring cells were negative. In concordance with prior studies, our data show these markers are specific but less sensitive for breast tumors when compared to ER and GATA-3 [21, 25]. Cases found to express GCDFP15 and mammaglobin expressed GATA3 and were often ER-positive.…”

Section: Discussionsupporting

confidence: 91%

Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers

et al. 2018

View full text Add to dashboard Cite

Signet ring morphology is recognized throughout the gastrointestinal tract. However, this pattern may be observed in other primary sites giving rise to diagnostic challenges in the work-up of metastases. Relatively newer immunohistochemical markers have not been evaluated in this context. We assessed expression patterns of several common immunohistochemical markers in tumors with Signet ring morphology to delineate a pragmatic approach to this differential diagnosis. Primary breast and gastrointestinal carcinomas showing Signet ring features were reviewed. Non-mammary and non-gastrointestinal tumors with this morphology were included for comparison. Estrogen receptor (ER), progesterone receptor (PR), E-cadherin, CK7, CK20, GCDFP-15, mammaglobin, CDX2, GATA-3, and HepPar-1 immunohistochemistry was performed. Expression patterns were compared between breast and gastrointestinal tumors as well as lobular breast and gastric tumors. Ninety-three cases were identified: 33 breast carcinomas including 13 lobular, 50 gastrointestinal tumors including 23 gastric, and 10 from other sites. ER (sensitivity=81.8%, specificity=100%, positive predictive value (PPV)=100%, negative predictive value (NPV)=89.3%) and GATA-3 (sensitivity=100%, specificity=98%, PPV=96.8%, NPV=100%) expression were associated with breast origin. CK20 (sensitivity=66.7%, specificity=93.3%, PPV=94.1%, NPV=63.6%) and CDX2 (sensitivity=72%, specificity=100%, PPV=100%, NPV=68.9%) demonstrated the strongest discriminatory value for gastrointestinal origin. These markers exhibited similar discriminatory characteristics when comparing lobular and gastric signet ring carcinomas. In a limited trial on metastatic breast and gastric cases, these markers successfully discriminated between breast and gastric primary sites in 15 of 16 cases. ER and GATA-3 are most supportive of mammary origin and constitute an effective panel for distinguishing primary breast from primary gastrointestinal Signet ring tumors when combined with CK20 and CDX2 immunohistochemistry.

show abstract

Section: Discussionsupporting

confidence: 91%

Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…19,20,22,24 Overall, SOX10 had a lower expression rate than other common markers in IBCs, regardless of molecular subtype. [1][2][3][4][5][6][7][8][9][10][11][12] However, in keeping with previous studies, [1][2][3][4]6,10,16,18,20,22,24 the current study confirmed that SOX10 was predominantly expressed in TNBCs, which constituted only a small proportion of IBCs, whereas other common markers were predominantly expressed in other more common molecular subtypes. SOX10 was found to be significantly associated with TNBC, whereas other common breast lineage markers were associated with non-TNBC.…”

Section: Discussionsupporting

confidence: 89%

“…Expression of GATA3, GCDFP15 and MGB has been reported in 32-100%, 23-78% and 48-73% of IBCs, respectively. [1][2][3][4][5][6][7][8][9][10][11][12] These markers showed high expression in hormonal receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)positive cancers, but low expression in triple-negative breast cancers (TNBCs). 1,4,6,12,13 Some studies reported GATA3 expression in >90% of HR-positive cancers, whereas only 20-66% of TNBCs showed expression when a certain clone of GATA3 (L50-823) was used.…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4][5][6][7][8][9][10][11][12] These markers showed high expression in hormonal receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)positive cancers, but low expression in triple-negative breast cancers (TNBCs). 1,4,6,12,13 Some studies reported GATA3 expression in >90% of HR-positive cancers, whereas only 20-66% of TNBCs showed expression when a certain clone of GATA3 (L50-823) was used. 6,10,[14][15][16][17] The expression rates of GCDFP15 and MGB in TNBCs were even lower (3-31% and 17-26%, respectively), with many positive cases showing only focal staining.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sry‐related high‐mobility‐group/HMG box 10 (SOX10) as a sensitive marker for triple‐negative breast cancer

Jamidi¹,

Aphivatanasiri

et al. 2020

Histopathology

View full text Add to dashboard Cite

Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer Aims: Confirmation of a breast origin for triple-negative breast cancer (TNBC) is sometimes problematic. The traditional breast markers GATA-binding protein 3 (GATA3), mammaglobin (MGB) and gross cystic disease fluid protein 15 (GCDFP15) have shown limitations in identifying TNBC. Here, we aimed to examine the diagnostic potential of the newly proposed TNBC marker, Sry-related high-mobility-group/HMG box 10 (SOX10). Methods and results: We analysed and compared SOX10 expression with GATA3, MGB and GCDFP15 expression in a test cohort of 1838 invasive breast cancers (IBCs) by using tissue microarrays. The findings from the test cohort were further examined with a validation cohort of 42 TNBCs in whole sections. The overall expression rates of SOX10, GATA3, MGB and GCDFP15 were 6.9%, 83.1%, 47.0%, and 34.8%, respectively. Among the TNBCs within this cohort, the expression rates of SOX10, GATA3, MGB and GCDFP15 were 31.3%, 34.5%, 27.9%, and 25.2%, respectively. SOX10 was strongly associated with TNBC (P < 0.001), whereas all other traditional markers were associated with non-TNBC (P < 0.001 for all). In addition, SOX10 was more correlated to basal-like breast cancer (BLBC) (P = 0.001) than five-marker-negative subtype among the TNBCs. A high expression rate of SOX10 (81%) was confirmed in the validation cohort. Additionally, SOX10 expression was inversely correlated with GATA3 and GCDFP15 expression, so they may complement each other in TNBC detection. The SOX10-GATA3 combination yielded a sensitivity of 60.3% for TNBC detection in the test cohort. Conclusion: SOX10 is a reliable marker for identifying TNBC, and complements GATA3. The SOX10-GATA3 combination may be used as a sensitive TNBC marker.

show abstract

“…In our study, GATA3 and GATA6 transcripts were identified as gene signatures for breast cancer and gastroesophageal cancer, respectively. Previous studies have indicated that GATA3 was weakly expressed in a wide variety of normal tissues, while its expression was remarkably elevated in breast cancer (Yang and Nonaka, 2010;Liu et al, 2012); moreover, GATA3 has been identified as a novel clinical marker for detecting primary and metastatic breast cancer (Cimino-Mathews et al, 2013;Krings et al, 2014;Shield et al, 2014;Braxton et al, 2015;Sangoi et al, 2016;Yang et al, 2017). GATA6 was initially cloned from rat gastric tissue, designated as GATA-GT1 (Tamura et al, 1994); however, recent studies have indicated that GATA6 was frequently overexpressed and/or amplified in human gastroesophageal cancer (Sulahian et al, 2014;Chia et al, 2015;Song et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

A Neural Network Framework for Predicting the Tissue-of-Origin of 15 Common Cancer Types Based on RNA-Seq Data

Zhang

Zhou

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Sequencing-based identification of tumor tissue-of-origin (TOO) is critical for patients with cancer of unknown primary lesions. Even if the TOO of a tumor can be diagnosed by clinicopathological observation, reevaluations by computational methods can help avoid misdiagnosis. In this study, we developed a neural network (NN) framework using the expression of a 150-gene panel to infer the tumor TOO for 15 common solid tumor cancer types, including lung, breast, liver, colorectal, gastroesophageal, ovarian, cervical, endometrial, pancreatic, bladder, head and neck, thyroid, prostate, kidney, and brain cancers. To begin with, we downloaded the RNA-Seq data of 7,460 primary tumor samples across the above mentioned 15 cancer types, with each type of cancer having between 142 and 1,052 samples, from the cancer genome atlas. Then, we performed feature selection by the Pearson correlation method and performed a 150-gene panel analysis; the genes were significantly enriched in the GO:2001242 Regulation of intrinsic apoptotic signaling pathway and the GO:0009755 Hormonemediated signaling pathway and other similar functions. Next, we developed a novel NN model using the 150 genes to predict tumor TOO for the 15 cancer types. The average prediction sensitivity and precision of the framework are 93.36 and 94.07%, respectively, for the 7,460 tumor samples based on the 10-fold cross-validation; however, the prediction sensitivity and precision for a few specific cancers, like prostate cancer, reached 100%. We also tested the trained model on a 20-sample independent dataset with metastatic tumor, and achieved an 80% accuracy. In summary, we present here a highly accurate method to infer tumor TOO, which has potential clinical implementation.

show abstract

GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors

Cited by 26 publications

References 32 publications

Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers

Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers

Sry‐related high‐mobility‐group/HMG box 10 (SOX10) as a sensitive marker for triple‐negative breast cancer

A Neural Network Framework for Predicting the Tissue-of-Origin of 15 Common Cancer Types Based on RNA-Seq Data

Contact Info

Product

Resources

About